GLP-1 RAs are one of the ever-increasing number of important drug classes used in the management of type 2 diabetes and are playing an increasing role within primary care. But when and in whom can they be used? And what impact do they have on disease progression and long-term complications?
This face-to-face meeting aims to provide you with practical information on how to optimise the use of GLP-1 RAs, in particular Ozempic® (semaglutide). You will have the opportunity to: